selpercatinib
Selected indexed studies
- Selpercatinib. (, 2012) [PMID:37665755]
- Selpercatinib. (, 2006) [PMID:33226749]
- First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. (N Engl J Med, 2023) [PMID:37870973]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Selpercatinib. (2012) pubmed
- Selpercatinib. (2006) pubmed
- First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. (2023) pubmed
- Selpercatinib: First Approval. (2020) pubmed
- Selpercatinib in the treatment of thyroid cancer. (2025) pubmed
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. (2022) pubmed
- Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC. (2023) pubmed
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. (2023) pubmed
- Selpercatinib. (2020) pubmed
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. (2020) pubmed